Read More 1 minute read Analyst Ratings News Price Target Upgrades Credit Suisse Upgrades Cinemark Hldgs to Neutral, Raises Price Target to $12 By Benzinga Newsdesk February 23, 5:45 AM Credit Suisse analyst Douglas Mitchelson upgrades Cinemark Hldgs (NYSE:CNK) from Underperform to Neutral and raises the price target from $9 to $12. CNK
Read More 1 minute read Analyst Ratings News Price Target Upgrades Piper Sandler Upgrades Wix.com to Neutral, Raises Price Target to $99 By Benzinga Newsdesk February 23, 5:06 AM Piper Sandler analyst Clarke Jeffries upgrades Wix.com (NASDAQ:WIX) from Underweight to Neutral and raises the price target from $80 to $99. WIX
Read More 1 minute read Analyst Color Analyst Ratings General Health Care Movers News Price Target Trading Ideas Upgrades Analyst Says This MedTech Giant Stock Offers ‘Too Much Optionality,’ Upgrades Rating By Vandana Singh February 22, 2:15 PM Raymond James upgraded Masimo Corporation (NASDAQ:MASI) from Market Perform To Outperform with a price target of $187 and says that no other company… AAPL
Read More 1 minute read Analyst Color Analyst Ratings Biotech General Health Care Movers News Price Target Small Cap Upgrades Analyst Sees Attractive Entry Opportunity After BioCryst’s Pipeline Setback By Vandana Singh February 22, 1:31 PM Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a setback on the early-stage BCX10013 study. The company… BCRX
Read More 1 minute read Analyst Color Analyst Ratings News Price Target Upgrades Nordson’s Steps To Diversify Despite Volatility, Margin Boost Initiatives Win Analyst Attention Who Prefers Buying The Dips By Anusuya Lahiri February 22, 1:16 PM KeyBanc analyst Jeffrey Hammond upgraded Nordson Corp (NASDAQ:NDSN) from Sector Weight to Overweight and a $255 price target. Nordson reported Q1 sales… NDSN
Read More 1 minute read Analyst Ratings News Price Target Upgrades Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target By Benzinga Newsdesk February 22, 8:29 AM Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target. BCRX
Read More 1 minute read Analyst Ratings News Price Target Upgrades Raymond James Upgrades Masimo to Outperform, Announces $187 Price Target By Benzinga Newsdesk February 22, 6:56 AM Raymond James analyst Jayson Bedford upgrades Masimo (NASDAQ:MASI) from Market Perform to Outperform and announces $187 price target. MASI
Read More 1 minute read Analyst Ratings News Price Target Upgrades DA Davidson Upgrades Shopify to Buy, Announces $50 Price Target By Benzinga Newsdesk February 22, 6:13 AM DA Davidson analyst Gil Luria upgrades Shopify (NYSE:SHOP) from Neutral to Buy and announces $50 price target. SHOP
Read More 1 minute read Analyst Ratings News Price Target Upgrades Citigroup Upgrades Alcoa to Buy, Raises Price Target to $65 By Benzinga Newsdesk February 22, 6:12 AM Citigroup analyst Alexander Hacking upgrades Alcoa (NYSE:AA) from Neutral to Buy and raises the price target from $55 to $65. AA
Read More 1 minute read Analyst Ratings News Price Target Upgrades Keybanc Upgrades Nordson to Overweight, Announces $255 Price Target By Benzinga Newsdesk February 22, 5:33 AM Keybanc analyst Jeffrey Hammond upgrades Nordson (NASDAQ:NDSN) from Sector Weight to Overweight and announces $255 price target. NDSN